Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BCR-ABL1 and CRLF2<sup>Re/Hi</sup><sub>,</sub> and that high CD99 mRNA levels are strongly associated with a high frequency of relapse, high proportion of positive for minimal residual disease at day 29 and poor overall survival in paediatric cohorts, which indicate that CD99 is a potential biomarker for BCP-ALL.
|
30484860 |
2019 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis.
|
30858550 |
2019 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
|
30835732 |
2019 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our report suggests a feasible pipeline, in terms of costs and reproducibility, aimed at characterizing and quantifying the genomic BCR-ABL1 rearrangement during MRD monitoring in CML patients.
|
29541390 |
2018 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BCR/ABL1 MRD negative patients at TP1 had a relapse risk similar to those who were IG/TR MRD negative (1/8 relapses).
|
29079599 |
2018 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
This study assesses their utility in BCR-ABL1 negative pediatric B-ALL, particularly with respect to end-induction minimal residual disease (MRD).
|
29199525 |
2018 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To address this, we studied 142 adults with ALL treated with hyperCVAD over a 10-year period who had MRD assessed by either multi-parameter flow cytometry or (for patients with Philadelphia chromosome positive ALL) reverse transcriptase polymerase chain reaction for the BCR-ABL1 translocation.
|
29318644 |
2018 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
|
29691899 |
2018 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, dual PP2A and BCR-ABL inhibition may be a valuable therapeutic strategy to synergistically target drug-insensitive LSCs that maintain minimal residual disease in patients.
|
29437150 |
2018 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pharmacological inhibition of c-FOS, DUSP1 and BCR-ABL eradicated MRD in multiple in vivo models, as well as in mice xenotransplanted with patient-derived primary CML cells.
|
28319094 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Current treatment with tyrosine kinase inhibitors is directed against the constitutively active ABL1 domain of the fusion protein, and minimal residual disease (MRD) after therapy is monitored by real-time quantitative PCR (RQ-PCR) of the fusion transcript.
|
28377570 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A 17-year-old girl with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with persistent minimal residual disease (MRD) who underwent standard chemotherapy was found to have a BCR-ABL1-like gene expression pattern.
|
27860260 |
2017 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Twelve cycles of maintenance therapy using a combination of VCR, PSL, and dasatinib are performed.In association with relapse, the minimal residual disease (MRD) of BCR-ABL chimeric gene and T-cell subsets are analyzed both before and after auto-PBSCT.
|
29384978 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
After switching to nilotinib, both BCR-ABL and BCR-ABL<sup>I</sup><sup>ns35bp</sup> became undetectable in 3 patients who attained complete molecular response (CMR), whereas in the remaining all 34 patients, BCR-ABL<sup>I</sup><sup>ns35bp</sup> was persistently detected, and minimal residual disease (MRD) fluctuated at low but detectable levels.
|
28801986 |
2017 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
|
28527402 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We observed a rapid decrease in minimal residual disease on molecular assessment with an MMR of P190-BCR-ABL/ABL = 0.01% confirmed by bone marrow revaluations at days +23, +59, +108, and +191 after the first day of salvage chemotherapy.
|
28810255 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, BCR-ABL1-independent resistance in the setting of effective BCR-ABL1 inhibition is recognized as a major contributor to minimal residual disease.
|
28673390 |
2017 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The non/late response rate and levels of minimal residual disease in the fusion-positive BCR-ABL1-like group were higher than in the non-BCR-ABL1-like B-others (p<0.01), and also higher, albeit not statistically significant, compared with the fusion-negative BCR-ABL1-like group.
|
27894077 |
2017 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
A high level of MRD was associated with high WBC counts, increased age, BCR-ABL1 fusion gene, MLL rearrangements and adverse karyotypes.
|
27212157 |
2016 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pre-transplant MRD level of 10 mutant copies of NPM1 per 10,000 Abelson murine leukemia viral oncogene homolog 1 (ABL) copies had the strongest statistical significance, and detection of higher MRD level (>10 NPM1-mutant copies) before alloHSCT was associated with increased overall mortality (hazard ratio=3.71; 95% confidence interval=1.55-9.06; p=0.004).
|
27798920 |
2016 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The combination of IKZF1 deletion and p210 BCR-ABL1 (p < 0.0001), high white blood cell count (p = 0.021), and minimal residual disease (p = 0.013) were associated with worse disease-free survival.
|
26892479 |
2016 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Early MRD kinetics is an important tool for new prognostication models with direct clinical impact irrespective of standard prognostic factors in patients with BCR-ABL negative ALL.
|
25997106 |
2016 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
By multivariate analysis, the factors independently associated with adverse relapse-free survival (RFS) were: bone marrow (BM)-WT1 ≥ 121/10(4) ABL copies (P = 0.02) and LAIP ≥ 0.2% (P = 0.0001) (after 1st consolidation) (RFS at the median follow up of 12.5 months: 51% vs. 82% [P < 0.0001] and 57% vs. 81%, respectively [P = 0.0003]) and PB-WT1 ≥ 16/10(4) ABL copies (P = 0.0001) (after 1st intensification) (RFS 43% vs. 95% [P < 0.0001]) Our data confirm the benefits of sequential MRD monitoring with both Q-PCR and MFC.
|
26715369 |
2016 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
BCR-ABL1 expression was studied in 248 samples from 65 patients with CML by determining the difference between MRD quantified by RT-qPCR and DNA-qPCR.
|
26837312 |
2016 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The threshold was set at 150 WT1 copies/104 ABL copies as the optimal cut-off value of MRD level post induction in childhood AML.
|
26221900 |
2015 |